BioAtla initiates strategic review, plans 70% workforce reduction
BioAtla’s Board has launched a formal strategic review to monetize its preclinical and clinical assets through sales, licensing deals, partnerships or other transactions. Concurrently, the company will implement a restructuring that cuts operating expenses and reduces its workforce by approximately 70% while retaining essential personnel.
1. Strategic Review Launch
BioAtla’s Board has initiated a formal review to explore strategic options including asset sales, licensing agreements, strategic partnerships, or other corporate transactions aimed at maximizing shareholder value. The process will assess both preclinical and clinical-stage assets but carries no assurance of a concluded transaction.
2. Workforce Reduction and Cost Cuts
As part of this review, the company will implement a restructuring plan targeting significant expense reductions by cutting approximately 70% of its workforce. BioAtla will retain employees deemed essential for continuing development of key assets and preserving value creation capabilities.
3. Advisor Engagement and Next Steps
BioAtla appointed Tungsten Advisors as exclusive strategic financial advisor to guide the evaluation process and potential transaction negotiations. The company will withhold further updates until the Board approves specific actions or determines disclosure requirements.